ProNAi Therapeutics Announces Pricing of Initial Public Offering

VANCOUVER, July 15, 2015 /CNW/ – ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering of 8,100,000 shares of its common stock at a price to the public of $17.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on July 16, 2015 under the symbol “DNAI.” In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,215,000 shares of common stock.

Read more: ProNAi Therapeutics Announces Pricing of Initial Public Offering